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Abstract
Background: This study examined receipt of guideline-concordant care (GCC) according to 
evidence-based treatment guidelines and quality measures and specific types of treatment among 
older women with breast cancer.
Patients and Methods: A total of 142,433 patients aged ≥66 years diagnosed with stage I–III 
breast cancer between 2007 and 2011 were identified in the SEER-Medicare linked database. 
Algorithms considering cancer characteristics and the appropriate course of care as per guidelines 
versus actual care received determined receipt of GCC. Multivariable logistic regression estimated 
the likelihood of GCC and specific types of treatment for women aged ≥75 versus 66 to 74 years.
Results: Overall, 39.7% of patients received GCC. Patients diagnosed at stage II or III, with 
certain preexisting conditions, and of nonwhite race were less likely to receive GCC. Patients with 
hormone-negative tumors, higher grade tumors, and greater access to oncology care resources 
were more likely to receive GCC. Patients aged ≥75 years were approximately 40% less likely to 
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receive GCC or adjuvant endocrine therapy, 78% less likely to have any surgery, 61% less likely to 
have chemotherapy, and about half as likely to have radiation therapy than those aged 66 to 74 
years.
Conclusions: Fewer than half of older women with breast cancer received GCC, with the lowest 
rates observed among the oldest age groups, racial/ethnic minorities, and women with later-stage 
cancers. However, patients with more aggressive tumor characteristics and greater access to 
oncology resources were more likely to receive GCC. Considering that older women have the 
highest incidence of breast cancer and that many are diagnosed at stages requiring more aggressive 
treatment, efforts to increase rates of earlier stage diagnosis and the development of less toxic 
treatments could help improve GCC and survival while preserving quality of life.
Background
More than 50 years of research has guided the development of evidence-based treatment 
guidelines for breast cancer, including those published by NCCN.1,2 Although the course of 
treatment for each woman is primarily determined by her tumor characteristics and extent of 
disease, multiple treatment pathways exist that are dependent on patient characteristics and 
preferences. However, not all patients receive guideline-concordant care (GCC). Vulnerable 
populations, such as racial and ethnic minorities or those who are socioeconomically 
disadvantaged, are more likely to experience treatment disparities.3–7 Independent of these 
characteristics, older women are less likely to receive GCC due to increasing age and 
declining health and functional status associated with older age.6,8,9 The NCCN Clinical 
Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer contain 2 age-based 
treatment concessions. The first is the omission of radiation therapy (RT) following breast-
conserving surgery (BCS) for patients aged ≥70 years with stage I, estrogen receptor (ER)–
positive breast cancer and that they should receive adjuvant endocrine therapy (AET) based 
on the CALGB C9343 trial findings.2,10,11 The second is the recommendation that the 
decision to treat women aged >70 years with chemotherapy be made on a case-by-case 
basis, considering patient preferences, health, and risks, citing insufficient evidence for this 
age group.2,12 Guidelines note that older women who received chemotherapy in trial studies 
experienced similar survival outcomes but had an increased risk for side effects and 
treatment-related mortality.13,14
Despite flexibility in treatment guidelines, treatment disparities reported by previous studies 
raise concern that older women are undertreated more frequently than warranted. Recent 
studies have reported that among women aged ≥65 years, 21% to 29% did not receive RT 
following BCS for early-stage breast cancer regardless of their ER status,4,15 67% with 
lymph node–positive disease did not receive chemotherapy,9 50% did not receive 
trastuzumab,16 and 17% to 40% did not receive AET when indicated.5 Moreover, age and 
comorbidity have been found to be the strongest predictors of treatment, irrespective of 
clinical indications.17–20 These findings are of particular concern considering that women 
aged ≥65 years represent 43% of newly diagnosed breast cancer cases,21 and that 
undertreatment is associated with worse disease-specific survival for many older patients.
15,17,20
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Although undertreatment is commonly reported among older women with breast cancer, it is 
difficult to discern how inappropriate or problematic this is if the treatment is in accordance 
with evidence-based treatment guidelines that provide age-based treatment considerations, 
depending on individual circumstances. Therefore, the extent to which older women with 
invasive breast cancer receive GCC, considering all available treatment options, remains 
unknown. Bearing these thoughts in mind, the goal of this study was to determine US 
population-based estimates of the prevalence and associations with GCC for breast cancer 
among older women, as well as receipt of specific types of treatments using the US 
population-based SEER-Medicare data.
Patients and Methods
Data Source and Cohort Definition
The SEER-Medicare linked database was created in a collaborative effort by the NCI and 
Centers for Medicare & Medicaid Services. SEER data are collected from 17 tumor 
registries representing 26% of the US population, and are successfully matched to Medicare 
enrollment records for 94% of patients aged ≥65 years.22 SEER-Medicare data contains 
information about date of diagnosis, cancer site, stage, tumor characteristics, treatment, 
healthcare use, patient enrollment and eligibility, selected demographic characteristics, and 
vital status information. Medicare claims are available for Part A (inpatient), Part B 
(outpatient), and Part D (prescription drug) services.23 County and state identifiers were 
used to link SEER-Medicare data to the US Department of Health & Human Service’s 2009 
Area Resource File (ARF) to identify the area-level health resources.24
We identified 431,212 women aged ≥66 years diagnosed with breast cancer as their first or 
only primary tumor between January 1, 2007, and December 31, 2011. We excluded women 
without a pathologic diagnosis (n=9,954) and those diagnosed with breast cancer at death or 
autopsy (n=30); who died within 366 days of diagnosis (n=23,729); diagnosed with stage 0 
or stage IV disease (n=105,189); not continuously enrolled in Medicare Parts A and B fee-
for-service programs for 12 months before and after diagnosis (n=9,469); not continuously 
enrolled in Medicare Part D services for 4 months before diagnosis and 12 months after 
diagnosis (n=124,231); enrolled in a health maintenance organization plan during the 12 
months before and after diagnosis (n=14,542); and whose records were missing tumor size 
(n=484) and surgeon specialty (n=1,151). The final analytic cohort consisted of 142,433 
patients (Figure 1).
Dependent Variables
The primary outcome was receipt of GCC, defined as treatment, including surgery, RT, 
chemotherapy, and AET, received according to the NCCN Guidelines for Breast Cancer, 
Version 1.2009.25 Measures assessed by this study remained unchanged in previous and later 
versions of the guidelines published during the cohort study period. Initiation of 
chemotherapy within 120 days of diagnosis, when indicated, as specified by the joint ASCO/
NCCN quality measures,26 and receipt of ER and progesterone receptor (PR) testing were 
also included in the definition of GCC. Hormone receptor testing was ascertained using a 
previously described method that considers documentation of a “positive,” “negative,” or 
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“borderline” ER and PR status as an indication that hormone receptor testing was conducted, 
and an “unknown” or “missing” status as an indication that testing was not conducted.27 
Receipt of GCC was determined using algorithms that compared the correct course of care 
with the actual care received (Figure 2). As stated in the NCCN Guidelines, omission of RT 
after BCS if the patient was aged ≥70 years; had stage I, ER-positive breast cancer; and 
received AET was considered GCC. Omission of chemotherapy, when indicated, was 
considered GCC among women aged >70 years. If chemotherapy was received, then time to 
initiation of chemotherapy was assessed. Surgery, RT, chemotherapy, and AET were 
ascertained by identifying ICD-9 diagnostic and procedure codes and Healthcare Common 
Procedure Coding System/ Current Procedural Terminology codes for generic drug names 
(see supplemental eTable 1, available with this article at JNCCN.org).
The secondary outcome was receipt of individual tests and treatments: ER testing, PR 
testing, BCS, mastectomy, RT, chemotherapy, initiation of chemotherapy within 120 days of 
diagnosis, and AET when indicated.
Independent Variables
Independent variables included year of diagnosis, age, preexisting chronic conditions, 
frequency of primary care provider (PCP) visits, clinical prognostic factors, oncology care 
resources, and demographic characteristics. Specific preexisting chronic conditions prevalent 
among older individuals examined were anxiety, depression, dementia, arthritis, 
osteoporosis, diabetes, hypertension, hyperlipidemia, heart disease, stroke, and chronic 
obstructive pulmonary disease, identified using methods described by the Working Group on 
Health Outcomes for Older Persons With Multiple Chronic Conditions.28 Frequency of PCP 
visits was calculated by counting the number of unique PCP claim dates recorded 1 year 
before diagnosis in the physician claims file and dividing by the lower and upper 50th 
percent median cutoff (low, high). Clinical prognostic factors examined were stage at 
diagnosis, tumor size, lymph node status, ER status, PR status, and tumor grade. Measures 
of oncology care resources were the density (low vs high) of area-level mammography 
screening centers and oncology treatment centers relative to each woman’s location of 
residence using data from the ARF, and were then categorized by the lower and upper 50th 
percent median cutoff. Surgeon specialty was assessed using provider specialty claims codes 
02 and 49 (general) and 83, 90, 91, and 98 (oncology) from the physician claims file variable 
“hcfaspec” to determine the type of surgeon seen (general only, oncology only, both). 
Demographic characteristics examined were race/ethnicity, marital status, 2010 Census 
measure of education and annual income, and metropolitan status.
Statistical Analysis
Pearson and Mantel-Haenszel chi-square tests were used to compare the proportions of 
patients receiving GCC. Multivariable logistic regression models estimated the adjusted 
odds of receiving GCC (yes vs no), adjusting for all covariates. A secondary analysis was 
performed to further investigate the association of age of receipt of GCC and specific tests 
and treatments, controlling for all other covariates using multivariable logistic regression 
models. Age was dichotomized by women aged ≥75 years versus 66 to 74 years, because 
findings from the primary analysis showed a significant decrease in GCC after 74 years of 
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age. Parameter estimates are presented as adjusted odds ratios (AORs) with their 
corresponding 95% CIs; P ≤.05 was considered statistically significant. All analyses were 
conducted using SAS 9.4 (SAS Institute Inc.). This study was approved for exemption by the 
West Virginia Institutional Review Board.
Results
Cohort Characteristics
Patient characteristics are presented in supplemental eTable 2. Most were aged >80 years at 
diagnosis, white, diagnosed at stage I, lymph node–negative, ER-positive, and diagnosed 
with hypertension and hyperlipidemia. Most patients received BCS (60.8%), RT (57.4%), 
and AET (49.7%). Overall, 39.7% received GCC.
Receipt of GCC
Rates of GCC were highest among women aged 70 to 74 years and lowest for those aged 
≥80 years (50.5% vs 28.1%; P<.001; supplemental eTable 2). Lower rates of GCC were 
observed among women with preexisting depression, dementia, arthritis, diabetes, or heart 
disease compared with those without these conditions. Women diagnosed at stage I had 
higher rates of GCC than those diagnosed at stages II and III (42.0% vs 37.2% and 36.9%, 
respectively; P<.001), as did women with hormone-negative and higher-grade tumors. 
Women treated by an oncology surgeon or both an oncology and general surgeon had higher 
rates of GCC than women treated by a general surgeon (37.9% and 43.3% vs 19.2%; P<.
001). White women had higher rates of GCC than those who were black, Hispanic/Latino, 
and other races (41.8% vs 32.5%, 36.5%, 37.2%, respectively; P<.001). Multivariable 
regression analyses confirmed findings of the bivariate analysis (Table 1). Compared with 
women aged 66 to 69 years, those aged ≥80 years were approximately half as likely to 
receive GCC (AOR, 0.52; 95% CI, 0.51–0.54). Women with hypertension (AOR, 1.15; 95% 
CI, 1.12–1.19) and stroke (AOR, 1.45; 95% CI, 1.38–1.52) were more likely to receive GCC 
than those without these conditions. Conversely, women with arthritis (AOR, 0.88; 95% CI, 
0.85–0.90), depression (AOR, 0.48; 95% CI, 0.46–0.51), dementia (AOR, 0.68; 95% CI, 
0.63–0.72), diabetes (AOR, 0.79; 95% CI, 0.77–0.81), hyperlipidemia (AOR, 0.91; 95% CI, 
0.88–0.93), and heart disease (AOR, 0.77; 95% CI, 0.75–0.80) were less likely to receive 
GCC. Compared with women diagnosed at stage I, those diagnosed at stage II (AOR, 0.64; 
95% CI, 0.61–0.68) and stage III (AOR, 0.66; 95% CI, 0.61–0.71) were less likely to receive 
GCC. Women with ER- and PR-negative tumors were more likely to receive GCC than those 
with positive tumors (AOR, 2.58; 95% CI, 2.46–2.70 and AOR, 1.15; 95% CI, 1.11–1.20, 
respectively). Women with moderately and poorly differentiated tumors were more likely to 
receive GCC than those with highly differentiated tumors. Women residing in an area with a 
high density of mammography screening centers or those treated by an oncology surgeon 
only or both an oncology and a general surgeon were more likely to receive GCC than 
women treated by a general surgeon only. Women who were black (AOR, 0.60; 95% CI, 
0.58–0.62), Hispanic/Latino (AOR, 0.70; 95% CI, 0.65–0.75), and of other races (AOR, 
0.57; 95% CI, 0.53–0.61) were less likely to receive GCC than white women.
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Receipt of Tests and Treatments
Compared with women aged 66 to 74 years at diagnosis, those aged ≥75 years were more 
than 40% less likely to receive GCC (AOR, 0.59; 95% CI, 0.57–0.60) or AET (AOR, 0.63; 
95% CI, 0.61–0.65), almost 80% less likely to have any type of surgery (AOR, 0.22; 95% 
CI, 0.20–0.24), approximately half as likely to have RT (AOR, 0.53; 95% CI, 0.52–0.54), 
and approximately 61% less likely to have chemotherapy (AOR, 0.39; 95% CI, 0.38–0.40) 
and 34% less likely to experience an appropriate time to chemotherapy (AOR, 0.66; 95% CI, 
0.63–0.69) (Table 2).
Discussion
This study evaluated the extent to which older women with invasive breast cancer receive 
GCC in accordance with NCCN and ASCO evidence-based guidelines using the large, 
population-based SEER-Medicare database. Findings showed that only 40% received GCC, 
and rates were lowest among the oldest women (aged ≥80 years). A recent study of women 
of all ages with breast cancer reported an 80% GCC rate, but also found that GCC decreased 
with age.29 The difference in rate of GCC reported between these studies is likely 
attributable to the difference in age composition of the study populations.
Interestingly, women between ages 70 and 74 years were more likely to receive GCC. A 
probable explanation for this finding is that RT is not recommended for a subset of women 
aged ≥70 years with stage I breast cancer, and the decision to treat with chemotherapy is 
recommended to be made on a case-by-case basis for women aged >70 years. Therefore, 
many women >70 years of age who did not receive these treatments still received GCC by 
definition. However, even after these age-based treatment exemptions were considered in the 
definition of GCC, rates of GCC began to decrease for those aged ≥75 years. Findings from 
comparisons made between women aged 66 to 74 and those aged ≥75 years also show that 
women aged ≥75 years were less likely to receive every type of treatment, even receipt of 
ER status testing and AET. This finding suggests that treatment decisions were made based 
on reasons other than clinical indications. As expected and consistent with previous 
research, rates of GCC were the lowest among women aged >80 years.9,17,28 However, a 
recent study reported no significant difference in overall survival between octogenarians and 
nonagenarians who did and did not receive adjuvant treatments for early-stage breast cancer.
30 Therefore, the lower rates of GCC observed among the oldest age groups of women may 
be reasonable, considering individual patient circumstances. Moreover, because of 
functional status, quality of life, and life expectancy, oncologists often cite increasing age, 
with or without comorbidity, as the primary reason for use of less aggressive treatment.31–35 
Patient preferences also play an important role in treatment decision-making, and older 
patients with breast cancer more frequently prefer to omit adjuvant treatments compared 
with younger patients.36 However, regardless of age or health, patients with hormone-
negative and higher-grade tumors were more likely to receive GCC, a finding that has also 
been reported by previous research.17
The increasing prevalence of chronic conditions and multimorbidity among elderly patients 
with cancer presents additional treatment challenges, and is often associated with 
undertreatment.4,20,37 This study found that the presence of specific conditions, such as 
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diabetes and heart disease, decreased the likelihood of GCC. Diabetes can decrease the 
likelihood of GCC by having a more severe impact on patient health, creating competing 
health demands and increasing the risk of treatment complications, intolerance, and adverse 
reactions,38–40 whereas certain other chronic conditions may increase the likelihood of GCC 
through increased contact with healthcare providers, without creating competing health 
demands and treatment complications. In fact, patients with breast cancer with a greater 
frequency of PCP visits were more likely to receive GCC.
This study has several strengths, including a comprehensive examination of the association 
between GCC among older women with breast cancer and health, clinical, oncology 
resource, and demographic characteristics using a large population-based data set. Complex 
algorithms were used to determine receipt of GCC by calculating the correct course of care 
according to each patient’s tumor characteristics and comparing that with the actual care 
received.
However, several limitations should be kept in mind when interpreting the results of this 
study. This study did not measure completion of RT or chemo-therapy, only the initiation of 
therapy. It also did not distinguish between the receipt of neoadjuvant and adjuvant 
chemotherapy. Neoadjuvant chemotherapy is given to some women to shrink larger tumors 
and provide an opportunity for BCS after clinical staging but before pathologic staging. 
Although tumor size was used to determine the need for postmastectomy RT, the number of 
positive lymph nodes was not. This study only accessed the presence of positive or negative 
nodes. Because the SEER program only began recording information about the status of 
HER2/neu breast cancer cases in 2011, this study did not assess treatment for HER2/neu-
positive tumors. Nor does SEER-Medicare collect information regarding results of any 
Oncotype testing that may influence treatment choices.
Conclusions
A little more than half of older women received GCC for breast cancer, even after 
incorporating age-based considerations into the definition of GCC. Variations in GCC by 
age group likely reflect the differing definitions of GCC by age, given than women aged ≥75 
years were less likely to receive certain treatments. However, patients with more aggressive 
breast cancer characteristics were more likely to receive GCC. Given that older women 
represent close to half of all newly diagnosed breast cancers, and many are diagnosed at 
stages that require RT or chemotherapy, increasing rates of earlier-stage diagnosis and the 
development of less toxic treatments could help to improve GCC and survival while 
preserving quality of life.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Flow diagram for study cohort selection.
Abbreviation: HMO, health maintenance organization.
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Guideline-concordant treatment options by tumor size and lymph node status.
Abbreviations: AET, adjuvant endocrine therapy; BCS, breast-conserving surgery; CT, 
chemotherapy; ER, estrogen receptor; ERT, estrogen receptor testing; N, nodal status; PR, 
progesterone receptor; PRT, progesterone receptor testing; RT, radiation therapy; T, tumor 
size.
aAET recommended when breast tumors are ER- and/or PR-positive.
bRecommended that, for women aged >70 years, the decision to treat with chemotherapy 
should be made on an individual patient basis.
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Table 1.
Multivariable Logistic Regression of Guideline-Concordant Care
Concordant vs Discordant
AOR 95% CI P Value
Year of diagnosis
 2007 1.00 Ref
 2008 1.08 1.04–1.13 <.001
 2009 1.07 1.03–1.11 <.001
 2010 1.39 1.33–1.45 <001
 2011 1.44 1.38–1.49 <.001
Age at diagnosis, y
 66–69 1.00 Ref
 70–74 1.48 1.43–1.53 <001
 75–79 1.01 0.97–1.05
 ≥80 0.52 0.51–0.54 <001
Health factors
 PCP visits
  Low 1.00 Ref
  High 1.16 1.13–1.19 <.001
 Anxiety
  Yes 1.08 1.03–1.13 .001
  No 1.00 Ref
 Depression
  Yes 0.48 0.46–0.51 <.001
  No 1.00 Ref
 Dementia
  Yes 0.68 0.63–0.72 <001
  No 1.00 Ref
 Arthritis
  Yes 0.88 0.85–0.90 <001
  No 1.00 Ref
 Osteoporosis
  Yes 0.96 0.92–1.00 .032
  No 1.00 Ref
 Diabetes
  Yes 0.79 0.77–0.81 <.001
  No 1.00 Ref
 Hypertension
  Yes 1.15 1.12–1.19 <.001
  No 1.00 Ref
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Concordant vs Discordant
AOR 95% CI P Value
 Hyperlipidemia
  Yes 0.91 0.88–0.93 <.001
  No 1.00 Ref
 Heart disease
a
  Yes 0.77 0.75–0.80 <001
  No 1.00 Ref
 Stroke
  Yes 1.45 1.38–1.52 <001
  No 1.00 Ref
 Chronic obstructive pulmonary disease
 Yes 0.99 0.95–1.03 .657
  No 1.00 Ref
Clinical prognostic factors
 Stage at diagnosis
  I 1.00 Ref
  II 0.64 0.61–0.68 <.001
  III 0.66 0.61–0.71 <.001
 Tumor size, cm
  <1 1.00 Ref
  1 to<2 0.79 0.77–0.82 <.001
  2–5 1.43 1.35–1.51 <.001
  >5 0.23 0.21–0.26 <.001
 Lymph nodes
  Positive 0.99 0.94–1.03 .585
  Negative 1.00 Ref
 ER status
  Positive 1.00 Ref
  Negative 2.58 2.46–2.70 <.001
  Borderline/Unknown 0.0 0.00–2.00 .715
 PR status
  Positive 1.00 Ref
  Negative 1.15 1.11–1.20 <001
  Borderline/Unknown 0.28 0.24–0.31 <.001
 Tumor grade
  Well-differentiated 1.00 Ref
  Moderately differentiated 1.27 1.23–1.31 <.001
  Poorly differentiated 1.51 1.45–1.57 <.001
  Undifferentiated/ Unknown 0.59 0.56–0.63 <001
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Concordant vs Discordant
AOR 95% CI P Value
Oncology care resources
 Mammography screening centers
  Low 1.00 Ref
  High 1.63 1.43–1.84 <.001
 Oncology treatment centers
  Low 1.00 Ref
  High 0.96 0.84–1.08 .476
 Specialty of treating surgeons
  General 1.00 Ref
  Oncology 1.62 1.52–1.73 <.001
  General & oncology 3.02 2.90–3.15 <001
Demographic characteristics
 Race/Ethnicity
  White 1.00 Ref
  Black 0.60 0.58–0.62 <001
  Hispanic/Latino 0.70 0.65–0.75 <.001
  Other 0.57 0.53–0.61 <001
 Education
  <15% college degree 1.04 1.01–1.07 .005
  ≥15% college degree 1.00 Ref
 Annual income
  ≤$35,000 1.03 1.00–1.06 .037
  >$35,OOO 1.00 Ref
 Married/Partnered
  Yes 1.00 Ref
  No 5 1.00–1.05 .079
 Region
  Metropolitan 0.69 0.66–0.73 <001
  Nonmetropolitan 1.00 Ref
Abbreviation: AOR, adjusted odds ratio; ER, estrogen receptor; PCP, primary care physician; PR, progesterone receptor.
a
Includes coronary artery disease and cardiac arrhythmia.
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Table 2.
Multivariable Logistic Regression of Treatment in Women Aged ≥75 Versus 66–74 Years
AOR 95% CI P Value
Guideline-concordant care
 Yes 0.59 0.57–0.60 <.001
 No 1.00 Ref
ER status tested
 Yes 0.91 0.91–0.91 <.001
 No 1.00 Ref
PR status tested
 Yes 1.00 1.00–1.00 <.001
 No 1.00 Ref
Received AET
 Yes 0.63 0.61–0.65 <.001
 No 1.00 Ref
Received any surgery
 Yes 0.22 0.20–0.24 <001
 No 1.00 Ref
Received BCS
 Yes 0.8B 0.82–0.87 <001
 No 1.00 Ref
Received mastectomy
 Yes 0.95 0.93–0.98 <.001
 No 1.00 Ref
Received radiation therapy
 Yes 0.53 0.52–0.54 <.001
 No 1.00 Ref
Received chemotherapy
 Yes 0.39 0.38–0.40 <.001
 No 1.00 Ref
Time to chemotherapy
 Appropriate 0.66 0.63–0.69 <.001
 Not appropriate 1.00 Ref
 No chemotherapy 1.93 1.84–2.02 <.001
Abbreviations: AET, adjuvant endocrine therapy; AOR, adjusted odds ratio; BCS, breast-conserving surgery; ER, estrogen receptor; PR, 
progesterone receptor.
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